Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 13/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20392486 | 0.95 | GLS (1.00) | GLSKMT2ASMN1; SMN2PKMRECQL | |
| SCHEMBL21325757 | 0.95 | GLS (0.86) | GLSKMT2ASMN1; SMN2PKMRECQL | |
| SCHEMBL15724986 | 0.95 | GLS (1.00) | GLSKMT2ASMN1; SMN2PKMRECQL | |
| SCHEMBL15724989 | 0.95 | GLS (1.00) | GLSKMT2ASMN1; SMN2PKMRECQL | |
| SCHEMBL15724994 | 0.95 | GLS (1.00) | GLSKMT2ASMN1; SMN2PKMRECQL | |
| SCHEMBL20392483 | 0.94 | GLS (0.84) | GLSKMT2ASMN1; SMN2RECQLMEN1 | |
| SCHEMBL17172576 | 0.90 | GLS (1.00) | GLSKMT2ARECQLMEN1ALDH1A1 | |
| SCHEMBL15724979 | 0.90 | GLS (1.00) | GLSKMT2ARECQLMEN1ALDH1A1 | |
| SCHEMBL15724974 | 0.90 | GLS (1.00) | GLSKMT2ARECQLMEN1ALDH1A1 | |
| SCHEMBL15724980 | 0.90 | GLS (1.00) | GLSKMT2ARECQLMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| WO-2015101958-A2 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS SA (CH) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885KMT2A 2349/4885SMN1; SMN2 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.